Table 4.
Inhaler preference outcomes from using the COPD Device Preference Questionnaire in the two Phase IIIa active comparator studies (113360/113374; ITT population)
| Patients receiving active Ellipta™ N=1,274* | Patients receiving active HandiHaler® N=418 | All patients N=1,692 | |
|---|---|---|---|
| Number of steps, n (%) | |||
| n | 1,228 | 404 | 1,632 |
| Ellipta™ | 714 (58) | 255 (63) | 969 (59) |
| HandiHaler® | 211 (17) | 65 (16) | 276 (17) |
| No preference | 303 (25) | 84 (21) | 387 (24) |
| Time needed to use, n (%) | |||
| n | 1,228 | 404 | 1,632 |
| Ellipta™ | 749 (61) | 268 (66) | 1,017 (62) |
| HandiHaler® | 181 (15) | 44 (11) | 225 (14) |
| No preference | 298 (24) | 92 (23) | 390 (24) |
| Ease of use, n (%) | |||
| n | 1,228 | 404 | 1,632 |
| Ellipta™ | 760 (62) | 260 (64) | 1,020 (63) |
| HandiHaler® | 199 (16) | 52 (13) | 251 (15) |
| No preference | 269 (22) | 92 (23) | 361 (22) |
Notes: N is the number of patients in the total population; n is the number of patients with analyzable data at the current time point.
*
This group includes patients receiving UMEC/VI, UMEC, or VI.
Abbreviations: COPD, chronic obstructive pulmonary disease; ITT, intent-to-treat; UMEC/VI, umeclidinium/vilanterol; UMEC, umeclidinium; VI, vilanterol.